Industry News

M and A Navigator: Deal pipeline –21 July
Patheon N.V. Announces Pricing of Initial Public Offering
CytoDyn posted a net loss of $25.7 million for its 2016 fiscal year that ended May 31, but the Vancouver-based biotechnology company says it has its eyes on the long haul as it works toward a "powerful" antibody to combat HIV. "The company has not generated revenue to date and will not generate product revenue in the foreseeable future," according to a Securities and Exchange Commission filing Tuesday. "The company expects to continue to incur operating losses as it proceeds..."/>
CytoDyn net loss persists to invest in HIV therapy [The Columbian, Vancouver, Wash.]
Perrigo Company plc, a leading global provider of Quality Affordable Healthcare Products ®, today announced the departure of Douglas Boothe, Executive Vice President and General Manager, Rx Pharmaceuticals. John Wesolowski, Senior Vice President of Rx Commercial Operations, will assume the role of Acting General Manager, Rx Pharmaceuticals. Perrigo's Chief Executive Officer John T. Hendrickson said, "John Wesolowski has the full confidence..."/>
Perrigo Announces Leadership Change in Rx Pharmaceuticals Segment
Amgen today announced that it has entered into an agreement with plaintiffs to resolve In re Amgen Inc. Securities Litigation, CV-07-2536 PSG, a previously disclosed securities class action lawsuit pending in the United States District Court for the Central District of California. The settlement class consists of purchasers of Amgen's publicly-traded securities during the period from April 22, 2004, through May 10, 2007,..."/>
Amgen Announces Settlement Of Securities Litigation
Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy. Included in this article is: Nobilis Health Corp.. Kenneth Efird will oversee Nobilis Health Corp.' s operating units across the nation, focusing on execution of the company's strategic plan, according to a press release issued on July 11. Prior to stepping in as president, Efird had served as..."/>
Nobilis Moves Forward with New President and New Canaccord Coverage
Emergent BioSolutions, Inc.. Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 are encouraged to contact the firm in advance of the September 19, 2016 lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate."/>
INVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm
Universal Health Services, Inc. announced today that its Board of Directors voted to pay a cash dividend of $0.10 per share on September 15, 2016 to shareholders of record as of September 1, 2016.. Universal Health Services, Inc. is one of the nation's largest hospital companies, operating, through its subsidiaries, behavioral health facilities, acute care hospitals, and ambulatory centers throughout the United States, Puerto Rico, the..."/>
Universal Health Services, Inc. Announces Dividend
ConforMIS, Inc. announced today that it will host a conference call on Monday, August 8, 2016, at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter 2016. To participate in the conference call, please call 877-809-6331 and use conference ID number 47277183.. The conference call will be hosted by Philipp Lang, MD, MBA, President and Chief Executive Officer, and Paul Weiner, Chief Financial Officer."/>
ConforMIS to Host Second Quarter 2016 Financial Results Conference Call and Webcast on August 8, 2016
Emergent BioSolutions, Inc. securities between January 11, 2016 and June 21, 2016. The lawsuit charges Emergent and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Emergent is a specialty biopharmaceutical company."/>
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. (EBS) and Encourages Investors to Contact the Firm
National Research Corporation today announced that it will provide an online Web simulcast of its 2016 second quarter conference call on Wednesday, August 3, 2016. The Company’ s results for the second quarter will be released after the close of the market on Tuesday, August 2, 2016.. The live broadcast of National Research Corporation’ s conference call will begin at 11:00 a.m. Eastern Time on August 3, 2016."/>
National Research Corporation to Broadcast Its 2016 Second Quarter Conference Call Live on the Internet
Emergent BioSolutions, Inc.. Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive, are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline. If you purchased shares of Emergent during the Class Period, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine,..."/>
IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Reminds Investors with Losses to Contact the Firm
RTI Surgical Inc., a global surgical implant company, announced today that it plans to release financial results from the second quarter 2016 on Wednesday, July 27, 2016, prior to the market open. RTI will host a conference call and simultaneous audio webcast to discuss second quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing 383-7419 or 666-3754."/>
RTI Surgical® Schedules 2016 Second Quarter Earnings and Conference Call for July 27, 2016
TherapeuticsMD, Inc., an innovative women’ s healthcare company, today announced that it will hold a conference call and live audio webcast to discuss second quarter financial and business results on Thursday, August 4. The conference call and webcast will take place at 4:30 p.m. ET."/>
TherapeuticsMD to Host Second Quarter Financial Results
Insys Therapeutics, Inc. today announced that the Company will release its financial results for the second quarter 2016 on Wednesday, August 3, 2016, before the U.S. financial markets open.. Following the release of the financial results, Dr. John N. Kapoor, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Time."/>
Insys Therapeutics to Report Second Quarter 2016 Results
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the financial results for the second quarter of 2016 after 5:00 PM ET on Tuesday, August 2, 2016.. Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to..."/>
Supernus to Host Second Quarter 2016 Earnings Conference Call
Joint Corp., a national operator, manager and franchisor of chiropractic clinics, today announced that, for second quarter 2016, it expects revenue to be in the range of $4.8 million to $5.0 million, a net loss in the range of$ million to$ million, and Adjusted EBITDA..."/>
The Joint Corp. Announces Preliminary Second Quarter 2016 Results
Radius Health, Inc., a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research 2016 Annual Meeting, September 16-19, 2016, at the Georgia World Congress Center..."/>
Radius Health Announces Multiple Presentations at the American Society for Bone and Mineral Research 2016 Annual Meeting September 16-19, 2016
Innoviva, Inc. announced today that it will report financial results for the second quarter ended June 30, 2016 after market close on Thursday July 28, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update. To participate in the live call dial 837-3908 from the U.S., or 890-8166 for international callers and enter Conference ID: 49092758."/>
Innoviva to Report Second Quarter 2016 Financial Results on July 28 at 5:00 p.m. EDT
Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Parminder“ Bobby” Singh, Ph.D., Corium’ s Chief Technology Officer and Vice President, Research and Development, will present clinical data from a Phase 1 pharmacokinetic study of Corium’ s once-weekly Corplex Donepezil product candidate at the..."/>
Corium to Present Clinical Data from a Phase 1 Pharmacokinetic Study of Once-Weekly Corplex™ Donepezil Transdermal System
Teva Pharmaceutical Industries Ltd. announced today that it successfully priced a debt offering by its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands II B.V., consisting of the following tranches:. €1.75 billion of 0.375% fixed rate senior notes maturing in 2020; €1.50 billion of 1.125% fixed rate senior notes maturing in 2024; and €0.75 billion of 1.625% fixed rate senior notes maturing in 2028.. The notes will be sold at a price..."/>
Teva Announces Pricing of Additional €4.0 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that it intends to withdraw lomitapide from the European Union and certain other global markets. In addition, the Company is reducing approximately 13 percent of its global workforce. This represents a reduction from year-end 2015 of..."/>
Aegerion Pharmaceuticals Announces Cost Reduction Plans
HTG Molecular Diagnostics, Inc., a provider of instruments and reagents for molecular profiling applications, today announced that it has obtained CE-IVD marking for its HTG EdgeSeq DLBCL Cell of Origin Assay and next-generation sequencing based HTG EdgeSeq system. There are approximately 79,000 non-Hodgkin lymphomas per year in the European Union, and as many as 40% of those are diagnosed as diffuse large B-cell lymphoma. The 2016 updates to the..."/>
HTG Molecular Diagnostics Obtains CE IVD Mark for Its HTG EdgeSeq DLBCL Cell of Origin Assay and HTG EdgeSeq System

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials854 Articles
Information Technology753 Articles
Consumer Discretionary706 Articles
Industrials543 Articles
Health Care466 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.